Could Psychedelics End Binge Drinking? A Breakthrough Patent Says Yes
Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biotech firm based in Vancouver, has been granted a new patent by the United States Patent and Trademark Office. As the company stated in a press release, this approval marks a significant milestone in Clearmind’s efforts to develop psychedelic-derived therapeutics, particularly in its MEAI-based program aimed at regulating binge behavior.
The Innovative Compound Behind Clearmind’s Success
The newly approved patent covers methods for regulating alcohol consumption and controlling binge behavior through the administration of amine aminoindane, including the innovative compound …